FDA Import Refusal SCS-0801226-4/11/1 — Boehringer Ingelheim Pharmaceuticals, Inc.
The FDA refused shipment SCS-0801226-4/11/1 from Boehringer Ingelheim Pharmaceuticals, Inc. (United States) on June 23, 2020. The refused product falls under Drugs and Biologics — INSULIN (INJ) (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- June 23, 2020
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 61PCY17 INSULIN (INJ) (ANTI-DIABETIC)
- Charges
- 75